Wiesel P H, Norton C, Roy A J, Storrie J B, Bowers J, Kamm M A
Department of Gastroenterology and Physiology, St Mark's Hospital, Northwick Park, Watford Road, Harrow HA1 3UJ, London, UK.
J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):240-3. doi: 10.1136/jnnp.69.2.240.
To determine whether gut focused behavioural treatment (biofeedback) is a useful therapy in multiple sclerosis patients referred for constipation, incontinence, or a combination of these symptoms. Most patients with multiple sclerosis complain of constipation, faecal incontinence, or a combination of the two. Patients rate these bowel symptoms as having a major impact on their life. Until now the management of these problems has been empirical, with a lack of evaluated therapeutic regimes.
Thirteen patients (eight women, median age 38 years, median duration of multiple sclerosis 10 years) complaining of constipation, with or without faecal incontinence underwent a median of four sessions of behavioural treatment. Anorectal physiological tests were performed before therapy. Impairment and disability were rated with the Kurtzke score and the Cambridge multiple sclerosis basic score (CAMBS). Patients were contacted a median of 14 months after completion of treatment.
A beneficial effect was attributed to biofeedback in five patients. Mild to moderate disability, quiescent and non-relapsing disease, and absence of progression of multiple sclerosis over the year before biofeedback were predictive of symptom improvement. No physiological test predicted the response to therapy.
Biofeedback retraining is an effective treatment in some patients with multiple sclerosis complaining of constipation or faecal incontinence. A response is more likely in patients with limited disability and a non-progressive disease course.
确定针对肠道的行为治疗(生物反馈疗法)对因便秘、大便失禁或二者皆有而转诊的多发性硬化症患者是否为一种有效的治疗方法。大多数多发性硬化症患者都有便秘、大便失禁或二者皆有的症状。患者认为这些肠道症状对他们的生活有重大影响。到目前为止,这些问题的处理一直是经验性的,缺乏经过评估的治疗方案。
13名主诉便秘、有或无大便失禁的患者(8名女性,中位年龄38岁,多发性硬化症中位病程10年)接受了中位4次行为治疗。治疗前进行了肛肠生理测试。用库尔茨克评分和剑桥多发性硬化症基础评分(CAMBS)对损伤和残疾程度进行评估。在治疗结束后中位14个月对患者进行随访。
5名患者的症状改善归因于生物反馈疗法。生物反馈治疗前一年中残疾程度为轻度至中度、病情静止且无复发、多发性硬化症无进展,这些情况可预测症状会改善。没有任何生理测试能预测对治疗的反应。
生物反馈再训练对一些主诉便秘或大便失禁的多发性硬化症患者是一种有效的治疗方法。残疾程度有限且疾病进程无进展的患者更有可能有反应。